Patents by Inventor Sheila Gujrathi

Sheila Gujrathi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATMENT OF DISEASES IN WHICH IL-13 ACTIVITY IS DETRIMENTAL USING ANTI-IL-13 ANTIBODIES
    Publication number: 20230220061
    Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
    Type: Application
    Filed: February 3, 2023
    Publication date: July 13, 2023
    Applicant: AbbVie Inc.
    Inventors: Gregg Timony, Sheila Gujrathi, Robert Peach, Allan Olson
  • METHODS OF TREATMENT OF DISEASES IN WHICH IL-13 ACTIVITY IS DETRIMENTAL USING ANTI-IL-13 ANTIBODIES
    Publication number: 20220281968
    Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
    Type: Application
    Filed: May 10, 2022
    Publication date: September 8, 2022
    Applicant: AbbVie Inc.
    Inventors: Gregg Timony, Sheila Gujrathi, Robert Peach, Allan Olson
  • Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies
    Patent number: 11390669
    Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an inter leukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: July 19, 2022
    Assignee: Abbvie, Inc.
    Inventors: Gregg Timony, Sheila Gujrathi, Robert Peach, Allan Olson
  • METHODS OF TREATMENT OF DISEASES IN WHICH IL-13 ACTIVITY IS DETRIMENTAL USING ANTI-IL-13 ANTIBODIES
    Publication number: 20210380674
    Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an inter leukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.
    Type: Application
    Filed: April 27, 2017
    Publication date: December 9, 2021
    Applicant: AbbVie Inc.
    Inventors: Gregg TIMONY, Sheila GUJRATHI, Robert PEACH, Allan OLSON
  • Treatment of inflammatory bowel disease (IBD)
    Publication number: 20060233797
    Abstract: The present invention concerns treatment of IBD, especially ulcerative colitis (UC), with an antibody that binds to CD20.
    Type: Application
    Filed: April 13, 2006
    Publication date: October 19, 2006
    Inventor: Sheila Gujrathi